Epizyme

Epizyme

Epizyme is a clinical stage biopharmaceutical company creating personalized therapeutics for patients with genetically defined cancers.  Epizyme has built a proprietary product platform that the company uses to create small molecule inhibitors of a 96-member class of enzymes known as histone methyltransferases (HMTs).  HMTs are part of the system of gene regulation, referred to as epigenetics, that controls gene
expression. Genetic alterations can result in changes to the activity of HMTs, making them oncogenic (cancer-causing).  By focusing on the genetic drivers of cancers, Epizyme’s targeted science seeks to match the right medicines with the right patients for a personalized approach to cancer treatment.

Epizyme completed an Initial Public Offering in May 2013 (NASDAQ:EPZM).

< Back to Portfolios